Italia markets closed

Dow Jones
39.811,18
-192,41(-0,48%)
Nasdaq
16.796,42
+110,45(+0,66%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0865
-0,0007(-0,07%)
Bitcoin EUR
64.032,05
+3.101,97(+5,09%)
CMC Crypto 200
1.451,19
+96,78(+7,15%)

NVCR Jan 2025 12.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

12,32

+1,52

(+14,07%)

In data: 10:24AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in